68,640 Shares in Kyverna Therapeutics, Inc. $KYTX Acquired by Man Group plc

Man Group plc purchased a new position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 68,640 shares of the company’s stock, valued at approximately $612,000.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter worth $27,931,000. AIGH Capital Management LLC acquired a new position in shares of Kyverna Therapeutics in the 2nd quarter valued at $24,911,000. Price T Rowe Associates Inc. MD increased its stake in Kyverna Therapeutics by 16.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,762,617 shares of the company’s stock worth $16,569,000 after purchasing an additional 250,418 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Kyverna Therapeutics in the 4th quarter worth about $15,667,000. Finally, Vanguard Group Inc. raised its holdings in Kyverna Therapeutics by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,322,625 shares of the company’s stock worth $7,936,000 after buying an additional 9,858 shares during the period. Institutional investors and hedge funds own 18.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $30.00.

Kyverna Therapeutics Trading Down 3.0%

NASDAQ:KYTX opened at $8.35 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 9.06 and a quick ratio of 9.06. Kyverna Therapeutics, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $13.67. The stock’s 50-day moving average is $8.20 and its two-hundred day moving average is $8.49. The stock has a market cap of $516.36 million, a PE ratio of -2.84 and a beta of 1.98.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.05. As a group, equities research analysts forecast that Kyverna Therapeutics, Inc. will post -2.7 earnings per share for the current fiscal year.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.